Abstract 216P
Background
Wilms tumor (WT) is a rare kidney cancer, but it is the most common malignant tumor of the kidneys of children. Although radical nephroectomy has been viewed as the gold standard surgery in Wilms tumor management for many years, partial nephrectomy has gained a lot of attention recently. So we conducted this study to compare the long term overall survival between those two different surgical techniques.
Methods
Using SEER database, we extracted the data of 636 patients with WT from 2000 to 2006. There were 55 (8.6%) patients underwent partial nephrectomy, while 581 (91.4%) of them underwent radical nephrectomy. Patients’ demographics were assessed.
Results
Our study showed that there is NO significant difference in Long-Term overall survival between partial nephrectomy and radical nephrectomy, where overall 10-year relative survival rates were 92.6% and 88.1%, respectively (p value =0.240). Subgroup analysis revealed NO significant difference in overall survival Except in patients with different age groups as seen in the table (p value <0.0001) but this could have been caused by the fact that few patients were recorded.
Table: 216P
Variables | Survival of Patients | p value | |
---|---|---|---|
Partial nephroectomy | Radical nephroectomy | ||
Sex Male Female | 96 % 89.7 % | 87.9 % 88.3 % | 0.821 |
Age 0- 9 10-19 20-39 40-59 60-79 | 91.5% 100%** 100%** 100%** 100%** | 89.9% 71.8% 36.4% 100% 66.7% | <0.0001*** |
Race White | 91% 100% _* % _* % | 88.8% 86.1% 88.9% 83.3% | 0.574 |
Black American Indian/Alaska Asian/pacific Islander | |||
Laterality Right left Bilateral | 89.9% 92.9% 95% | 90.1% 85.8% 92% | 0.175 |
Highly significant P-value ≤ 0.001.
**few no. of cases _.
*no recorded patients.
Conclusions
There is NO significant difference in overall 10-year survival between partial nephrectomy and radical nephrectomy. So, we recommend the application of partial nephrectomy in the appropriate patients to preserve as much kidney tissue and function as possible especially in bilateral WT. Further studies should be conducted on larger number of patients and they should study the efficacy of chemotherapy in patients undergoing partial nephrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mira Mohamed Mostafa.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract